CI
RPRX icon

Cooper Investors’s Royalty Pharma RPRX Stock Holding History

Cooper Investors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.21M Sell
164,249
-47,572
-22% -$2.48M 4.23% 8
2026
Q1 		$10.2M Sell
211,821
-174,619
-45% -$7.65M 4.14% 5
2025
Q4 		$14.9M Sell
386,440
-21,996
-5% -$839K 4.96% 4
2025
Q3 		$14.4M Sell
408,436
-5,726
-1% -$207K 3.94% 8
2025
Q2 		$14.9M Sell
414,162
-2,374
-0.6% -$78.7K 2.71% 12
2025
Q1 		$13M Hold
416,536
– – 2.11% 22
2024
Q4 		$10.6M Buy
416,536
+7,332
+2% +$194K 1.67% 26
2024
Q3 		$11.6M Sell
409,204
-1,980
-0.5% -$54.8K 1.72% 25
2024
Q2 		$10.8M Hold
411,184
– – 1.65% 23
2024
Q1 		$12.5M Buy
411,184
+18,390
+5% +$542K 0.72% 30
2023
Q4 		$11M Buy
392,794
+71,400
+22% +$1.96M 0.66% 30
2023
Q3 		$9.88M Buy
+321,394
New +$9.55M 0.79% 25
2023
Q1 		$11.5M Sell
320,264
-66,856
-17% -$2.48M 0.98% 22
2022
Q4 		$15.3M Sell
387,120
-1,594
-0.4% -$66.5K 1.44% 21
2022
Q3 		$15.6M Buy
388,714
+16,488
+4% +$704K 1.48% 21
2022
Q2 		$15.6M Sell
372,226
-48,855
-12% -$2M 1.36% 24
2022
Q1 		$16.4M Buy
421,081
+7,473
+2% +$293K 1.15% 22
2021
Q4 		$16.5M Sell
413,608
-529,769
-56% -$20.6M 1.04% 23
2021
Q3 		$34.1M Buy
943,377
+342,876
+57% +$13.3M 2.26% 19
2021
Q2 		$24.6M Buy
600,501
+422,767
+238% +$18M 1.61% 26
2021
Q1 		$7.75M Buy
177,734
+148,860
+516% +$7.06M 0.58% 33
2020
Q4 		$1.45M Buy
+28,874
New +$1.23M 0.12% 41

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cooper Investors's RPRX Position: Q2 2026 in Review

Cooper Investors reduced its Royalty Pharma (RPRX) stake by 22% in Q2 2026, selling an estimated $2.48M and leaving 164,249 shares worth $9.21M. The position accounts for 4.23% of the portfolio, ranked #8.

Cooper Investors first reported a position in RPRX in Q4 2020 and has held it in 22 quarters since. The position peaked at $34.1M in Q3 2021. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Cooper Investors held 164,249 shares of Royalty Pharma worth $9.21M as of Q2 2026.
  • Cooper Investors sold 47,572 Royalty Pharma shares in Q2 2026, an estimated $2.48M.
  • Royalty Pharma made up 4.23% of Cooper Investors's portfolio in Q2 2026, its #8 holding.
  • Cooper Investors first reported a position in Royalty Pharma in Q4 2020 and has held it in 22 quarters since.
  • Cooper Investors's Royalty Pharma position peaked at $34.1M in Q3 2021.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Cooper Investors's 13F filing for Q2 2026, filed 7 Jul 2026.